Alan Minsk Discusses Breaking Down Pharma in the Current Environment on FDA Watch Podcast

AGG Food & Drug chair Alan Minsk was featured on an episode of the FDA Watch podcast, sharing his thoughts on the potential effects that FDA staffing cuts may have on drug and biologics approvals and how the current environment may affect investments in drug and biotech development.

They also discuss what companies can do amid agency staffing shortages, how FDA can aim to include all demographics of patients in trials, and much more.

To learn more and listen, please click here.